|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The time required to identify DS-TB and MDR-TB in pure culture MTB and leftover sputum sediments from patients are 3 days and 4-6 days, respectively.
|
29801598 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H<sub>37</sub>Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.
|
30025351 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, the heteronuclear bis-isatin 4i (MIC: 25 and 16 μg/mL) was most active against MTB H37Rv and MDR-TB strains, and could act as a lead for further optimization.
|
29631015 |
2018 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most active hybrid 8i with MIC of 50 µg/mL against MTB H37Rv and MDR-TB, also has excellent cytotoxicity profile (CC50: 128 µg/mL).
|
29243578 |
2017 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that the Anyplex MTB/NTM MDR-TB assay is an efficient and rapid method for the diagnosis of pulmonary and extrapulmonary TB and the detection of isoniazid resistance.
|
26491178 |
2016 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results were compared with those of three molecular assays: Xpert MTB/RIF assay (MTB is Mycobacterium tuberculosis), Sacace MTB Real-TM resistance, and AdvanSure MDR-TB GenoBlot assay (MDR is multidrug resisitant).
|
24797357 |
2015 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study acquired miRNA data from sensitive MTB and MDR MTB strains using NGS techniques, and this identification miRNAs may serve as an invaluable resource for revealing the molecular basis of the regulation of expression associated with the mechanism of drug‑resistance in MTB.
|
26324150 |
2015 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
MTB-DR-RIF 9G membrane: a platform for multiplex SNP detection of multidrug-resistant TB.
|
25967151 |
2015 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Xpert-MTB/Rif is one of the most frequently used molecular screening tests for multidrug-resistant tuberculosis worldwide.
|
23850949 |
2013 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GenoType MTBDRplus assay has been validated as a rapid and reliable first-line diagnostic test on AFB-positive sputum or MTB isolates for INH resistance, RIF resistance, and MDR-TB in Bangkok, Thailand.
|
20487550 |
2010 |
|
Tuberculosis, Multidrug-Resistant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diverse population of MDR-MTB in Scotland, along with a low incidence of drug-resistant M. tuberculosis, has implications for the control of the organism and prevention of its spread.
|
10074516 |
1999 |